Delivery Order SPE2DB22D2206-SPE2DB25FJM25
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $30,927.58 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This is a firm fixed-price, non-set-aside contract executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion global pharmaceutical support vehicle running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) under a firm fixed-price contract valued at approximately $12.0K. This award, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, represents a non-competitive delivery order placed against AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The order will be fulfilled from the contractor's facility in...
- The Defense Logistics Agency awarded a delivery order valued at $39,491.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets in a quantity of 30 units, with a ceiling value of $87,792.14. This firm fixed-price delivery order, awarded on July 23, 2025, represents a non-set-aside competitive award with an ultimate completion date of July 24, 2025. The pharmaceutical products will be delivered to the company's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,138.54 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 28, 2025, with completion targeted for July 29, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vehicle running through December 2026 that provides comprehensive pharmaceutical and...
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $74,493.95 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (quantity: 30s) on August 8, 2025, with completion targeted for August 11, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical supply vehicle extending...
- The Defense Logistics Agency awarded a delivery order valued at $42,368.91 to AmerisourceBergen Drug Corp for RINVOQ ER 30 MG tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a $28,416.82 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award carries no set-aside designation, reflecting the company's proven capability to...
- The Defense Logistics Agency awarded a $46,037.03 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30 units. The contract is non-competitive with no set-aside designation and carries an ultimate completion date of July 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJM25Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) valued at $16,770.69 under a firm fixed-price contract type. The award, issued on August 18, 2025, with an ultimate completion date of August 19, 2025, represents a competitively awarded non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, performed the work at its corporate office location. This delivery order is a child contract under the company's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vehicle running through December 2026 that enables comprehensive pharmaceutical support for military healthcare programs worldwide. RINVOQ ER (upadacitinib) is an approved prescription medication used in the treatment of rheumatoid arthritis and other inflammatory conditions. The delivery order fulfills a specific medical supply need within the Defense Health Agency's pharmaceutical procurement framework, leveraging AmerisourceBergen's established position as a critical vendor in the federal medical supply chain. The company's extensive federal contract portfolio demonstrates its capability to meet complex pharmaceutical procurement requirements across multiple therapeutic domains, with contract awards ranging substantially in value and supporting military and veteran healthcare systems globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.8k | 8/18/25 |